An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

Trial Profile

An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs DI Leu16 IL2 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Alopexx Oncology
  • Most Recent Events

    • 06 Dec 2016 Status changed from recruiting to completed.
    • 15 Jan 2015 Planned primary completion date changed to 1 Jul 2017 as reported by ClinicalTrials.gov.
    • 15 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top